T-cell-based therapy is comprised of TILs, which are extracted from the tumor, activated ex vivo, expanded and reinfused in the patient along with immune enhancing adjuvants, such as interleukin-2 (IL-2), to induce a durable immunological response against the tumor cells. The gene discussed is IL2; the disease is neoplasm.